$8.160
+0.020 (+0.25%)終値時点
RGLS のニュース
RGLS のイベント
Sixteen option delistings on July 22nd
Option delistings effective July 22nd include Radius Recycling, Inc. - Class A Common Stock (RDUS), PHX Minerals Inc. (PHX), LSEA Stock (LSEA), KRON Stock (KRON), Juniper Networks, Inc. (JNPR), INZY Stock (INZY), HARTFORD SCHRODERS COMMODITY STRATEGY ETF (HCOM), EVRI Stock (EVRI), Enstar Group Limited - Ordinary Shares (ESGR), Dada Nexus (DADA), GRANITESHARES 1X SHORT AMD DAILY ETF (AMDS), AGS Stock (AGS), RGLS Stock (RGLS), SWTX Stock (SWTX), WisdomTree Battery Value Chain and Innovation Fund (WBAT), and X Stock (X).
Novartis completes acquisition of Regulus Therapeutics
Novartis (NVS) announced that it has successfully completed its acquisition of Regulus Therapeutics (RGLS). With the completion of the acquisition, shares of common stock of Regulus have ceased trading on the Nasdaq Stock Market and Regulus is now an indirect wholly owned subsidiary of Novartis. As a result of the merger, each share issued and outstanding and not tendered in the tender offer was canceled and extinguished and automatically converted into the right to receive the same consideration, including the CVR, per share payable in the tender offer. "We are pleased to complete this transaction and take the next step in advancing clinical development for a potential first-in-class medicine that can help treat patients suffering from ADPKD - autosomal dominant polycystic kidney disease - the most common genetic cause of renal failure worldwide. We are excited to welcome the talented team at Regulus to Novartis as we continue to build on our pipeline in renal disease with high unmet medical need," said Shreeram Aradhye, President, Development and Chief Medical Officer, Novartis.
Novartis announces expiration of Regulus Therapeutics tender offer
Novartis (NVS) announced that its previously announced tender offer by Redwood Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis, to acquire all of the outstanding shares of common stock of Regulus Therapeutics (RGLS), in exchange for $7.00 in cash per share, subject to any applicable withholding and without interest thereon, plus one contingent value right per share, representing the right to receive one contingent payment of $7.00 in cash, subject to any applicable withholding and without interest thereon, upon the achievement of a regulatory milestone, expired at one minute past 11:59 p.m., New York City Time, on June 24. Computershare Trust Company, N.A., the depositary for the offer, has advised that, as of the Expiration Time, approximately 56,374,397 Shares were validly tendered and not validly withdrawn pursuant to the Offer, representing approximately 74.49% of the issued and outstanding Shares immediately prior to the expiration time. The parties expect the transaction to close on June 25, promptly following the acceptance of all shares validly tendered and not validly withdrawn pursuant to the offer.
Novartis announces expiration of HSR waiting period of Regulus offer
Novartis (NVS) announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, in connection with Novartis' previously announced tender offer to acquire all of the outstanding shares of common stock of Regulus Therapeutics Inc. (RGLS), in exchange for $7.00 in cash per Share, subject to any applicable withholding and without interest thereon, plus one contingent value right per share, representing the right to receive one contingent payment of $7.00 in cash, subject to any applicable withholding and without interest thereon, upon the achievement of a regulatory milestone. The expiration of the HSR Act waiting period occurred at 11:59 p.m., New York City Time, on June 20. "Expiration of the waiting period under the HSR Act satisfies one of the conditions necessary for the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of April 29, 2025, among Novartis, Redwood Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis, and Regulus, including the tender offer and the subsequent merger, which remain subject to the condition that there be validly tendered and not validly withdrawn, immediately prior to the Expiration Time a number of Shares that, together with any Shares then owned by Novartis, Purchaser or any of their direct or indirect wholly owned subsidiaries, represents at least one more Share than 50% of the total number of all the outstanding Shares immediately prior to the Expiration Time. The offer will expire one minute past 11:59 p.m., New York City Time, on June 24, 2025, unless the tender offer is otherwise extended or earlier terminated," the company stated.
Regulus reports Q1 EPS (15c), consensus (26c)
As of March 31, 2025, Regulus had $65.4M in cash, cash equivalents and short-term investments. Expects cash runway to extend into early 2026. "We recently announced that we have entered into an agreement to be acquired by Novartis, whose established global development and commercial capabilities will potentially bring farabursen to patients with ADPKD, who currently have limited treatment options," said CEO Jay Hagan. "We've made important progress with farabursen so far this year, having announced positive results from the completed fourth cohort of patients in March, reporting evidence of a mechanistic dose response based on urinary PC1 and PC2 levels, and results suggesting that kidney volume growth rate was halted after only a relatively short treatment period. We look forward to investigating further as we head towards initiation of the pivotal Phase 3 trial in Q3 of this year."
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。